Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v5-EN | Version v4-EN | |
---|---|---|
Language | English | English |
Date Updated | 2017-03-13 | 2017-03-13 |
Drug Identification Number | 02248361 | 02248361 |
Brand name | VIVAXIM | VIVAXIM |
Common or Proper name | Combined purified Vi polysaccharide typhoid and inactivated hepatitis A vaccine | Combined purified Vi polysaccharide typhoid and inactivated hepatitis A vaccine |
Company Name | SANOFI PASTEUR LIMITED | SANOFI PASTEUR LIMITED |
Ingredients | SALMONELLA TYPHI VI CAPSULAR POLYSACCHARIDE VACCINE HEPATITIS A VACCINE, INACTIVATED | SALMONELLA TYPHI VI CAPSULAR POLYSACCHARIDE VACCINE HEPATITIS A VACCINE, INACTIVATED |
Strength(s) | 25MCG 160UNIT | 25MCG 160UNIT |
Dosage form(s) | SOLUTION SUSPENSION | SOLUTION SUSPENSION |
Route of administration | INTRAMUSCULAR | INTRAMUSCULAR |
Packaging size | 1 x 1.0 mL (single dose) dual chamber syringe / 1 seringue (dose unique) à double compartiment de 1,0 mL | 1 x 1.0 mL (single dose) dual chamber syringe |
ATC code | J07CA | J07CA |
ATC description | BACTERIAL AND VIRAL VACCINES, COMBINED | BACTERIAL AND VIRAL VACCINES, COMBINED |
Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
Anticipated start date | 2016-11-16 | 2016-11-16 |
Actual start date | 2016-11-16 | 2016-11-16 |
Estimated end date | 2018-03-01 | 2018-03-01 |
Actual end date | ||
Shortage status | Actual shortage | Actual shortage |
Tier 3 Status | No | No |
Company comments | Supply disruptions are anticipated in the private market. | Supply disruptions are anticipated in the private market. |
Health Canada comments |